Se­cu­ra Bio to keep of­fer­ing blood can­cer drug de­spite neg­a­tive ODAC vote, OS ques­tions

Se­cu­ra Bio says it has no plans to change the mar­ket­ing sta­tus of its PI3K in­hibitor Copik­tra (du­velis­ib), which won full ap­proval in Sep­tem­ber 2018 …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.